Last reviewed · How we verify
NCT06566066: DEEPTYPE
Register for Patients With Thyroid Hormone Resistance.
trial testing no intervention in Hypothyroidism in 200 participants. Currently enrolling.
14 July 2029
Quick facts
| Lead sponsor | Charite University, Berlin, Germany |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 200 |
| Start date | 1 July 2021 |
| Primary completion | 14 July 2029 |
| Estimated completion | 31 July 2029 |
| Sites | 1 location across Germany |
Drugs / interventions tested
- no intervention
Conditions studied
- Hypothyroidism — all drugs for Hypothyroidism →
- Global Developmental Delay — all drugs for Global Developmental Delay →
- Intellectual Disability — all drugs for Intellectual Disability →
- Dystonia — all drugs for Dystonia →
Sponsor
Charite University, Berlin, Germany
Who can join
Eligibility, any sex, with Hypothyroidism or Global Developmental Delay. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Thyroid hormones (TH) play a pivotal role in the development and function of the mammalian brain. Patients with impaired thyroid hormone transport into the brain tissue or in the case of defective local thyroid hormone receptor (collectively referred to as thyroid hormone resistance) subsequently experience psychomotor disabilities. The "DEEPTYPE" registry has been established with the objective of intensifying the genotyping and, in particular, the neurological phenotyping of patients exhibiting deficiencies in either the thyroid hormone transporter (MCT8) or the thyroid hormone receptor alpha (THRα). The objective of this registry-based study is to enhance the diagnostic yield for MCT8 and THRα deficiencies by employing the serum fT3/fT4 ratio as a more sophisticated screening parameter. Furthermore, the investigators will study the genomic regulation of both genes and attempt to identify further coding and non-coding mutations that result in TH resistance. The patient registry "DEEPTYPE" will document the retrospective and prospective clinical data of identified children in a comprehensive manner. This will enable the identification of three key groups: (i) patients with non-coding mutations, (ii) patients with milder phenotypes presenting only with a subset of symptoms seen in both "classic" conditions, and (iii) patients who are ready for clinical trials.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Patients with Allan-Herndon-Dudley Syndrome (MCT8 Deficiency) Display Symptoms of Parkinsonism in Childhood and Respond to Levodopa/Carbidopa Treatment.
Wilpert NM, Hewitt AL, Pons R, Henke MT, et al · · 2025 · cited 2× · PMID 40088079 · DOI 10.1002/mds.30152
Verify or expand the search:
- PubMed search for NCT06566066
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of no intervention
Trials testing the same drug.
- NCT07480057 — Assessment of Changes in Bone Mineral Metabolism After Liver Transplantation by Bone Mineral Densitometry · recruiting
- NCT07253506 — Turkish Adaptation, Validity, and Reliability Study of the Patient Experience With Treatment and Self-Management Scale i · not yet recruiting
- NCT07253519 — The Relationship Between Mood and Insomnia Severity and Caregiver Burden in Caregivers of Stroke · not yet recruiting
- NCT07194096 — Stress Hyperglycemia Ratio and Postoperative Delirium · not yet recruiting
- NCT07240337 — Botulinum Toxin Applications in Hemiplegic Patients · recruiting
Other recruiting trials for Hypothyroidism
Currently open trials in the same condition.
- NCT07060118 — Gluten Free Diet in Hashimoto's Hypothyroidism · NA · recruiting
- NCT06757712 — Periodization Resistance Training on Quality of Life in Females With Hypothyroidism · NA · recruiting
- NCT06731764 — Novel Approaches to the Treatment of Hypothyroidism · Phase 2, PHASE3 · recruiting
- NCT06826248 — Clinical Efficacy of Darqeen Capsule for the Management of Hypothyroidism Associated with Female Reproductive Hormonal I · EARLY_PHASE1 · active not recruiting
- NCT07421869 — SNUH Immune Checkpoint Inhibitor-induced Hypothyroidism Recovery Trial · NA · recruiting
Other Charite University, Berlin, Germany trials
Trials by the same sponsor.
- NCT07486167 — Influence of Lung Volume Optimization Maneuver on Cardiac Output and Lung Compliance in Ventilated Children With Congeni · Phase 1, PHASE2 · not yet recruiting
- NCT07476729 — International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 (IntReALL BCP 2020) · Phase 3 · not yet recruiting
- NCT07503054 — Ovarian Cancer Screening and AI · NA · not yet recruiting
- NCT07529197 — Observational Study on Immunoadsorption (IA) in Patients With Autoantibody-Positive Post-Infectious ME/CFS · recruiting
- NCT07388693 — Feasibility of Integrating Olfactory Stimuli Into Virtual Reality Cue Exposure for Patients With Alcohol Dependence · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06566066 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Charite University, Berlin, Germany
- Last refreshed: 22 August 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06566066.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing